Luo et al. linked high PCSK9 expression with poor prognosis in lung adenocarcinoma, noting that PCSK9 inhibitors might counter this by inducing mitochondrial dysfunction in lung cancer cells [34]. This evidence concerns the gene PCSK9 and lung carcinoma.